Erschienen in:
02.06.2016 | Original Article – Cancer Research
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
verfasst von:
Naoki Takahashi, Satoru Iwasa, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Natsuko Tsuda Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 8/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Immune checkpoint molecules are key targets for the treatment of various malignancies. Due to the heterogeneity of advanced gastric cancer (GC), the role of programmed cell death ligand 1 (PD-L1) expression as a tumor biomarker remains controversial.
In this study, the prognostic value of soluble PD-L1 (sPD-L1) levels in serum samples was assessed in patients with metastatic GC.
Methods
All patients received first-line treatment with fluoropyrimidine and platinum chemotherapy, and trastuzumab was added for HER2-positive patients. Serum levels of sPD-L1 were measured by enzyme-linked immunosorbent assay.
Results
Among 75 metastatic GC patients, the median serum sPD-L1 level was 0.704 ng/ml (range <0.156–3.214). Serum sPD-L1 was significantly higher in patients with a high versus a low white blood cell count at baseline. When the cutoff value was set as the median, multivariate analyses showed that high sPD-L1 levels were associated with worse overall survival compared with low sPD-L1 levels (HR 2.218, 95 % CI 1.139–4.320, P = 0.019). Regardless of HER2 status, overall survival tended to be shorter in patients with high sPD-L1 compared with low sPD-L1. There was no significant association between sPD-L1 level and progression-free survival on the first-line treatment of metastatic GC.
Conclusions
High serum levels of sPD-L1 correlated with worse overall survival on the first-line chemotherapy in metastatic GC patients.